219 related articles for article (PubMed ID: 31375313)
1. Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017-18: a test-negative case-control study.
Li Y; Zhou Y; Cheng Y; Wu P; Zhou C; Cui P; Song C; Liang L; Wang F; Qiu Q; Guo C; Zeng M; Long L; Cowling BJ; Yu H
Lancet Child Adolesc Health; 2019 Oct; 3(10):697-704. PubMed ID: 31375313
[TBL] [Abstract][Full Text] [Related]
2. Hand, Foot, and Mouth Disease in China: Modeling Epidemic Dynamics of Enterovirus Serotypes and Implications for Vaccination.
Takahashi S; Liao Q; Van Boeckel TP; Xing W; Sun J; Hsiao VY; Metcalf CJ; Chang Z; Liu F; Zhang J; Wu JT; Cowling BJ; Leung GM; Farrar JJ; van Doorn HR; Grenfell BT; Yu H
PLoS Med; 2016 Feb; 13(2):e1001958. PubMed ID: 26882540
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of enterovirus A71 vaccine in severe hand, foot, and mouth disease cases in Guangxi, China.
Jiang L; Wang J; Zhang C; He W; Mo J; Zeng J; Chen M; Tan Y; Ning C
Vaccine; 2020 Feb; 38(7):1804-1809. PubMed ID: 31892446
[TBL] [Abstract][Full Text] [Related]
4. The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China.
Jiang H; Zhang Z; Rao Q; Wang X; Wang M; Du T; Tang J; Long S; Zhang J; Luo J; Pan Y; Chen J; Ma J; Liu X; Fan M; Zhang T; Sun Q
Emerg Microbes Infect; 2021 Dec; 10(1):619-628. PubMed ID: 33682641
[TBL] [Abstract][Full Text] [Related]
5. [Clinical analysis of 555 outpatients with hand, foot and mouth diseases caused by different enteroviruses].
Cui P; Li Y; Zhou CC; Zhou YH; Song CL; Qiu Q; Wang F; Guo C; Han SJ; Liang L; Yuan Y; Zeng MY; Yue J; Long L; Qin XH; Li Z; Chen XL; Zou YP; Cheng YB; Yu HJ
Zhonghua Er Ke Za Zhi; 2019 Jun; 57(6):445-451. PubMed ID: 31216802
[No Abstract] [Full Text] [Related]
6. Effectiveness of Enterovirus 71 inactivated vaccines against hand, foot, and mouth disease: A test-negative case-control study.
Zhang Y; Cui J; Liu F; Song Y; Wang Q; Liu Y; Zhang Y; Li Z; Chang Z
Hum Vaccin Immunother; 2024 Dec; 20(1):2330163. PubMed ID: 38544389
[TBL] [Abstract][Full Text] [Related]
7. The transfer and decay of maternal antibodies against enterovirus A71, and dynamics of antibodies due to later natural infections in Chinese infants: a longitudinal, paired mother-neonate cohort study.
Wei X; Yang J; Gao L; Wang L; Liao Q; Qiu Q; Luo K; Yu S; Zhou Y; Liu F; Chen Q; Zhang J; Dai B; Yang H; Zhou J; Xing W; Chen X; He M; Ren L; Guo J; Luo L; Wu P; Chen Z; van Doorn HR; Cauchemez S; Cowling BJ; Yu H
Lancet Infect Dis; 2021 Mar; 21(3):418-426. PubMed ID: 33031750
[TBL] [Abstract][Full Text] [Related]
8. Molecular epidemiology and clinical features of hand, foot and mouth disease requiring hospitalization after the use of enterovirus A71 inactivated vaccine in chengdu, China, 2017-2022: a descriptive study.
Duan X; Zhang C; Wang X; Ren X; Peng H; Tang X; Zhang L; Chen Z; Ye Y; Zheng M; Zhong W; Chen X; Zeng Y; Yuan P; Long L
Emerg Microbes Infect; 2022 Dec; 11(1):2510-2519. PubMed ID: 36103331
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of enterovirus A71 vaccine against pediatric HFMD and disease profile of post-vaccination infection.
Duan X; Zhang L; Ding L; Zhang C; Chen Z; Cheng Y; Wang X; Peng H; Tang X; Ren X; Liao J; Yang S; Zhu Y; Luo W; Zeng Y; Yuan P; Long L
Vaccine; 2024 Apr; 42(9):2317-2325. PubMed ID: 38433065
[TBL] [Abstract][Full Text] [Related]
10. Is a multivalent hand, foot, and mouth disease vaccine feasible?
Klein M; Chong P
Hum Vaccin Immunother; 2015; 11(11):2688-704. PubMed ID: 26009802
[TBL] [Abstract][Full Text] [Related]
11. Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing, China.
Wang X; An Z; Huo D; Jia L; Li J; Yang Y; Liang Z; Wang Q; Wang H
Hum Vaccin Immunother; 2019; 15(5):1183-1190. PubMed ID: 30779680
[TBL] [Abstract][Full Text] [Related]
12. Epidemical and etiological study on hand, foot and mouth disease following EV-A71 vaccination in Xiangyang, China.
Meng XD; Tong Y; Wei ZN; Wang L; Mai JY; Wu Y; Luo ZY; Li S; Li M; Wang S; Wei S; Gong W; Zhang W; Hu X; Huang J; Shi J; Yang G; Meng S; Wang Z; Guan X; Shen S
Sci Rep; 2020 Dec; 10(1):20909. PubMed ID: 33262488
[TBL] [Abstract][Full Text] [Related]
13. The spatial-temporal distribution and etiological characteristics of hand-foot-and-mouth disease before and after EV‑A71 vaccination in Kunming, China, 2017-2020.
Wang M; Chen T; Peng J; Luo Y; Du L; Lu Z; He J; Liu C; Gan Q; Ma W; Cun Z; Zheng Q; Chen W; Chen Y; Han M; Liu G; Li J
Sci Rep; 2022 Oct; 12(1):17028. PubMed ID: 36220850
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and managements of severe hand, foot and mouth disease caused by enterovirus A71 and coxsackievirus A16 in Shanghai, China.
Cai K; Wang Y; Guo Z; Yu H; Li H; Zhang L; Xu S; Zhang Q
BMC Infect Dis; 2019 Mar; 19(1):285. PubMed ID: 30917800
[TBL] [Abstract][Full Text] [Related]
15. Enterovirus spectrum from the active surveillance of hand foot and mouth disease patients under the clinical trial of inactivated Enterovirus A71 vaccine in Jiangsu, China, 2012-2013.
Yao X; Bian LL; Lu WW; Li JX; Mao QY; Wang YP; Gao F; Wu X; Ye Q; Xu M; Li XL; Zhu FC; Liang ZL
J Med Virol; 2015 Dec; 87(12):2009-17. PubMed ID: 26010334
[TBL] [Abstract][Full Text] [Related]
16. Epidemiological surveillance of hand, foot and mouth disease in Shanghai in 2014-2016, prior to the introduction of the enterovirus 71 vaccine.
Li J; Pan H; Wang X; Zhu Q; Ge Y; Cai J; Li Y; Xia A; Hu J; Zeng M
Emerg Microbes Infect; 2018 Mar; 7(1):37. PubMed ID: 29559626
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine.
Yang B; Liu F; Liao Q; Wu P; Chang Z; Huang J; Long L; Luo L; Li Y; Leung GM; Cowling BJ; Yu H
Euro Surveill; 2017 Dec; 22(50):. PubMed ID: 29258646
[TBL] [Abstract][Full Text] [Related]
18. Development of single-step multiplex real-time RT-PCR assays for rapid diagnosis of enterovirus 71, coxsackievirus A6, and A16 in patients with hand, foot, and mouth disease.
Puenpa J; Suwannakarn K; Chansaenroj J; Vongpunsawad S; Poovorawan Y
J Virol Methods; 2017 Oct; 248():92-99. PubMed ID: 28662914
[TBL] [Abstract][Full Text] [Related]
19. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles.
Liu CC; Guo MS; Wu SR; Lin HY; Yang YT; Liu WC; Chow YH; Shieh DB; Wang JR; Chong P
Antiviral Res; 2016 May; 129():58-66. PubMed ID: 26899790
[TBL] [Abstract][Full Text] [Related]
20. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases.
Mao Q; Wang Y; Bian L; Xu M; Liang Z
Emerg Microbes Infect; 2016 Jul; 5(7):e75. PubMed ID: 27436364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
